Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
11.01 +0.01 (+0.09%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 11.10 +0.09 (+0.82%) 17:28 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
10.88
Day High
11.18
Open 10.91
Previous Close 11.00 11.00
Volume 8,016,500 8,016,500
Avg Vol 7,545,265 7,545,265
Stochastic %K 94.24% 94.24%
Weighted Alpha -1.37 -1.37
5-Day Change +0.86 (+8.47%) +0.86 (+8.47%)
52-Week Range 8.73 - 13.06 8.73 - 13.06
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,750,174
  • Shares Outstanding, K 713,549
  • Annual Sales, $ 124,800 K
  • Annual Income, $ 4,349 M
  • EBIT $ -1,002 M
  • EBITDA $ -980 M
  • 60-Month Beta 1.25
  • Price/Sales 68.38
  • Price/Cash Flow N/A
  • Price/Book 1.43

Options Overview Details

View History
  • Implied Volatility 31.96% ( -2.62%)
  • Historical Volatility 42.23%
  • IV Percentile 19%
  • IV Rank 22.59%
  • IV High 82.20% on 04/04/25
  • IV Low 17.31% on 07/12/24
  • Put/Call Vol Ratio 0.30
  • Today's Volume 133
  • Volume Avg (30-Day) 249
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 55,097
  • Open Int (30-Day) 56,475

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.73 +26.12%
on 04/07/25
Period Open: 10.67
11.18 -1.52%
on 04/25/25
+0.34 (+3.19%)
since 03/25/25
3-Month
8.73 +26.12%
on 04/07/25
Period Open: 11.17
11.51 -4.34%
on 02/10/25
-0.16 (-1.43%)
since 01/24/25
52-Week
8.73 +26.12%
on 04/07/25
Period Open: 10.88
13.06 -15.66%
on 09/09/24
+0.13 (+1.19%)
since 04/25/24

Most Recent Stories

More News
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

IMVT : 14.72 (-2.32%)
ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Roivant Sciences Tops Q3 Expectations

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

ROIV : 11.01 (+0.09%)
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching

President Trump's cabinet is comprised of millionaires, billionaires and leaders in business who founded or led public companies. Here's the TRUMP index stocks.

PYPL : 65.34 (+0.88%)
TSLA : 284.95 (+9.80%)
FOUR : 80.28 (-0.43%)
TKO : 157.10 (+1.17%)
LBRT : 12.17 (unch)
ROIV : 11.01 (+0.09%)
DJT : 26.14 (-0.04%)
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

ROIVW : 2.75 (-3.85%)
ROIV : 11.01 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 11.47
2nd Resistance Point 11.32
1st Resistance Point 11.17
Last Price 11.01
1st Support Level 10.87
2nd Support Level 10.72
3rd Support Level 10.57

See More

52-Week High 13.06
Fibonacci 61.8% 11.40
Last Price 11.01
Fibonacci 50% 10.89
Fibonacci 38.2% 10.38
52-Week Low 8.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective